PF-3845 [1196109-52-0]
P200000
Estimated Purity≥98%
Product group Chemicals
Overview
- SupplierLKT Laboratories
- Product NamePF-3845 [1196109-52-0]
- Delivery Days Customer7
- CertificationResearch Use Only
- Estimated Purity≥98%
- FormatDMSO (>45 mg/mL)
- Scientific DescriptionFAAH inhibitor.; PF3845
- Storage Instruction-20°C
- UNSPSC12352200
References
- Booker L, Kinsey SG, Abdullah RA et al. The fatty acid hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. Br J Pharmacol. 2012 Apr;165(8):2485-96. PMID: 21506952. Ramesh D, Gamage TF, Vanuytsel T et al. Dual Inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice. Neuropsychopharmacology. 2013 May;38(6):1039-49. PMID: 23303065 Tchantchou F, Tucker LB, Fu AH, et al. The fatty acid amide hydrolase inhibitor PF-3845 promotes neuronal survival, attenuates inflammation and improves functional recovery in mice with traumatic brain injury. Neuropharmacology. 2014 Oct;85:427-39. PMID: 24937045 Ghosh S, Kinsey SG Liu QS et al. Full Fatty ACid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimemetic Side Effects in Mice. J Pharmacol Exp Ther. 2015 Aug;354(2):111-20. PMID25998048.